Employees Retirement System of Texas Has $2.32 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Employees Retirement System of Texas trimmed its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,042 shares of the biopharmaceutical company's stock after selling 15,560 shares during the quarter. Employees Retirement System of Texas' holdings in Bristol-Myers Squibb were worth $2,321,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $25,000. Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $34,000. Finally, Tacita Capital Inc bought a new position in Bristol-Myers Squibb during the 4th quarter worth $39,000. Institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Up 0.9%

Shares of BMY stock traded up $0.41 on Friday, hitting $48.26. The company had a trading volume of 20,756,575 shares, compared to its average volume of 13,134,972. The stock's 50-day moving average is $50.49 and its two-hundred day moving average is $55.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market cap of $98.21 billion, a P/E ratio of -10.92, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the business earned ($4.40) EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.14%. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group dropped their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Piper Sandler began coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Finally, Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.